- Home
- INBX vs EOS Comparison
INBX vs EOS Comparison
Compare INBX & EOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INBX | EOS |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.7M | 1.1B |
| IPO Year | 2024 | 2004 |
Fundamental Metrics
Financial Performance| Metric | INBX | EOS |
|---|---|---|
| Price | $102.50 | $23.03 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $150.00 | N/A |
| AVG Volume (30 Days) | ★ 442.3K | 124.4K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 550.00 | N/A |
| 52 Week Low | $12.80 | $19.44 |
| 52 Week High | $155.29 | $24.49 |
Technical Indicators
Market Signals| Indicator | INBX | EOS |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 62.99 |
| Support Level | $99.20 | $21.75 |
| Resistance Level | $153.14 | $23.42 |
| Average True Range (ATR) | 11.61 | 0.30 |
| MACD | -3.13 | 0.01 |
| Stochastic Oscillator | 7.41 | 93.75 |
Price Performance
Historical ComparisonAbout INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About EOS Eaton Vance Enhance Equity Income Fund II
Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in common stocks. It invests in a portfolio of large and mid-cap securities in sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.